Showing 4081-4090 of 8866 results for "".
- Analysis Reveals Pre- and Post-COVID-19 Teledermatology Usage and Barriershttps://practicaldermatology.com/news/teledermatology-platforms-usage-and-barriers-a-cross-sectional-analysis-of-united-states-based-dermatologists-pre-and-post-covid-19/2462231/Dermatologists have increasingly turned to teledermatology to enhance patient care, but a recent study highlights crucial disparities in platform usage and functionality among practitioners. Researchers used cross-sectional pre-validated survey in 2021 and sought to discern va
- Roflumilast Formulations Show Favorable Tolerability Across Several Trials: Analysishttps://practicaldermatology.com/news/roflumilast-formulations-show-favorable-tolerability-across-several-trials-analysis/2462229/Investigator- and patient-rated assessments indicated that topical roflumilast was tolerable and did not cause discomfort, according to a new analysis of data from several clinical trials.
- Benzoyl Peroxide 2.6% Cleanser Effective at Reducing Acne Lesionshttps://practicaldermatology.com/news/benzoyl-peroxide-26-cleanser-effective-at-reducing-acne-lesions/2462228/A benzoyl peroxide 2.6% (BPO) complexion clearing acne cleanser (CCAC) was effective at reducing acne, a new study reports.
- ARCADIA 1 and 2: Nemolizumab Reduces Itch, Sleep Disturbance in Atopic Dermatitishttps://practicaldermatology.com/news/arcadia-nemolizumab-reduces-itch-sleep-disturbance-in-atopic-dermatitis/2462226/Nemolizumab, an interleukin-31 (IL-31) receptor alpha antagonist, demonstrated significant efficacy in adults and adolescents with atopic dermatitis (AD) in a pair of identical trials, according to new study results pre
- For Alopecia Areata, Discontinuation of Baricitinib Linked with Loss of Benefithttps://practicaldermatology.com/news/for-alopecia-areata-discontinuation-of-baricitinib-linked-with-loss-of-benefit/2462225/Results from a randomized substudy of the BRAVE-AA1 study suggested that patients with severe alopecia areata who withdrawal from treatment with baricitinib also lose the treatment benefit.
- Interim Analysis: Tralokinumab Improves Quality of Life in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/interim-analysis-tralokinumab-improves-quality-of-life-in-moderate-to-severe-atopic-dermatitis/2462224/Tralokinumab, an interleukin-13 (IL-13) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, was shown to improve several quality of life measures, a 6-month interim analysis sugg
- Long-Term Analysis Shows Upadacitinib Safe Up to 5 Years for Moderate to Severe ADhttps://practicaldermatology.com/news/long-term-analysis-shows-upadacitinib-safe-up-to-5-years-for-moderate-to-severe-ad/2462222/Upadacitinib for the treatment of moderate-to-severe atopic dermatitis (AD) was shown to have an acceptable safety profile at 5 years, according to a new integrated analysis.
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with mode
- BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HShttps://practicaldermatology.com/news/be-heard-analysis-bimekizumab-maintains-treatment-response-at-48-weeks-in-hs/2462220/A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clin
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <